<SEC-DOCUMENT>0001213900-20-033152.txt : 20201026
<SEC-HEADER>0001213900-20-033152.hdr.sgml : 20201026
<ACCEPTANCE-DATETIME>20201026083044
ACCESSION NUMBER:		0001213900-20-033152
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		7
CONFORMED PERIOD OF REPORT:	20201025
ITEM INFORMATION:		Other Events
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20201026
DATE AS OF CHANGE:		20201026

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Citius Pharmaceuticals, Inc.
		CENTRAL INDEX KEY:			0001506251
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				273425913
		STATE OF INCORPORATION:			NV
		FISCAL YEAR END:			0930

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-38174
		FILM NUMBER:		201259122

	BUSINESS ADDRESS:	
		STREET 1:		11 COMMERCE DRIVE
		STREET 2:		1ST FLOOR
		CITY:			CRANFORD
		STATE:			NJ
		ZIP:			07016
		BUSINESS PHONE:		(908) 967-6676

	MAIL ADDRESS:	
		STREET 1:		11 COMMERCE DRIVE
		STREET 2:		1ST FLOOR
		CITY:			CRANFORD
		STATE:			NJ
		ZIP:			07016

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	Trail One, Inc.
		DATE OF NAME CHANGE:	20110314

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	TrailOne, Inc.
		DATE OF NAME CHANGE:	20101119
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>ea128836-8k_citiuspharma.htm
<DESCRIPTION>CURRENT REPORT
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="text-indent: 0; font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"></P>

<!-- Field: Rule-Page --><DIV STYLE="margin: 0; width: 100%; text-indent: 0"><DIV STYLE="margin: 0; font-size: 1pt; border-top: Black 2pt solid; border-bottom: Black 1pt solid; text-indent: 0">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="text-indent: 0; font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</P>

<P STYLE="margin: 0; font: 10pt Times New Roman, Times, Serif; text-align: center; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">UNITED
STATES</FONT></P>

<P STYLE="margin: 0; font: 10pt Times New Roman, Times, Serif; text-align: center; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">SECURITIES
AND EXCHANGE COMMISSION</FONT></P>

<P STYLE="margin: 0; font: 10pt Times New Roman, Times, Serif; text-align: center; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Washington,
D.C. 20549</FONT></P>

<P STYLE="margin: 0; font: 10pt Times New Roman, Times, Serif; text-align: center; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">__________________</FONT></P>

<P STYLE="margin: 0; font: 10pt Times New Roman, Times, Serif; text-align: center; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="margin: 0; font: 10pt Times New Roman, Times, Serif; text-align: center; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>FORM
8-K</B></FONT></P>

<P STYLE="margin: 0; font: 10pt Times New Roman, Times, Serif; text-align: center; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">__________________</FONT></P>

<P STYLE="margin: 0; text-align: center; font: 10pt Times New Roman, Times, Serif; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="margin: 0; font: 10pt Times New Roman, Times, Serif; text-align: center; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">CURRENT
REPORT</FONT></P>

<P STYLE="margin: 0; font: 10pt Times New Roman, Times, Serif; text-align: center; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pursuant
to Section 13 or 15(d) of</FONT></P>

<P STYLE="margin: 0; font: 10pt Times New Roman, Times, Serif; text-align: center; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
Securities Exchange Act of 1934</FONT></P>

<P STYLE="margin: 0; font: 10pt Times New Roman, Times, Serif; text-align: center; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="margin: 0; font: 10pt Times New Roman, Times, Serif; text-align: center; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Date
of Report (Date of earliest event reported) <U>October 25, 2020</U></FONT></P>

<P STYLE="margin: 0; font: 10pt Times New Roman, Times, Serif; text-align: center; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">__________________</FONT></P>

<P STYLE="margin: 0; font: 10pt Times New Roman, Times, Serif; text-align: center; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="margin: 0; font: 10pt Times New Roman, Times, Serif; text-align: center; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><U>Citius
Pharmaceuticals, Inc.</U></B></FONT></P>

<P STYLE="margin: 0; font: 10pt Times New Roman, Times, Serif; text-align: center; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(Exact
name of registrant as specified in its charter)</FONT></P>

<P STYLE="margin: 0; font: 10pt Times New Roman, Times, Serif; text-align: center; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">__________________</FONT></P>

<P STYLE="margin: 0; font: 10pt Times New Roman, Times, Serif; text-align: center; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="margin: 0; font: 10pt Times New Roman, Times, Serif; text-align: center; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Nevada</U></FONT></P>

<P STYLE="margin: 0; font: 10pt Times New Roman, Times, Serif; text-align: center; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(State
or other jurisdiction of incorporation)</FONT></P>

<P STYLE="text-indent: 0; font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="padding: 0; border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center; width: 49%; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">333-206903</FONT></TD>
    <TD STYLE="padding: 0; text-align: center; font: 10pt Times New Roman, Times, Serif; width: 2%; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="padding: 0; border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center; width: 49%; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">27-3425913</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="padding: 0; text-align: center; font: 10pt Times New Roman, Times, Serif; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(Commission
    File Number)</FONT></TD>
    <TD STYLE="padding: 0; text-align: center; font: 10pt Times New Roman, Times, Serif; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="padding: 0; text-align: center; font: 10pt Times New Roman, Times, Serif; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(IRS
    Employer Identification No.)</FONT></TD></TR>
</TABLE>
<P STYLE="text-indent: 0; font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="padding: 0; border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center; width: 49%; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">11
    Commerce Drive, 1st Floor, Cranford, NJ</FONT></TD>
    <TD STYLE="padding: 0; text-align: center; font: 10pt Times New Roman, Times, Serif; width: 2%; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="padding: 0; border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center; width: 49%; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">07016</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="padding: 0; text-align: center; font: 10pt Times New Roman, Times, Serif; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(Address
    of principal executive offices)</FONT></TD>
    <TD STYLE="padding: 0; text-align: center; font: 10pt Times New Roman, Times, Serif; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="padding: 0; text-align: center; font: 10pt Times New Roman, Times, Serif; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(Zip
    Code)</FONT></TD></TR>
</TABLE>
<P STYLE="text-indent: 0; font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="text-indent: 0; font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Registrant's
telephone number, including area code <U>(908) 967-6677</U></FONT></P>

<P STYLE="text-indent: 0; font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">__________________</FONT></P>

<P STYLE="text-indent: 0; font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="text-align: justify; text-indent: 0; font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Check
the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant
under any of the following provisions:</FONT></P>

<P STYLE="text-indent: 0; font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="padding: 0; font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-indent: 0">&#9744;<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></TD>
    <TD STYLE="padding: 0; font: 10pt Times New Roman, Times, Serif; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Written
    communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="padding: 0; font: 10pt Times New Roman, Times, Serif; text-indent: 0">&#9744;</TD>
    <TD STYLE="padding: 0; font: 10pt Times New Roman, Times, Serif; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Soliciting
    material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="padding: 0; font: 10pt Times New Roman, Times, Serif; text-indent: 0">&#9744;</TD>
    <TD STYLE="padding: 0; font: 10pt Times New Roman, Times, Serif; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pre-commencement
    communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="padding: 0; font: 10pt Times New Roman, Times, Serif; text-indent: 0">&#9744;</TD>
    <TD STYLE="padding: 0; font: 10pt Times New Roman, Times, Serif; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pre-commencement
    communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))</FONT></TD></TR>
</TABLE>
<P STYLE="text-indent: 0; font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="text-indent: 0; font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Securities
registered pursuant to Section 12(b) of the Act:</FONT></P>

<P STYLE="text-indent: 0; font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="padding: 0; border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center; width: 32%; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Title
    of each class</FONT></TD>
    <TD STYLE="padding: 0; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center; width: 2%; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="padding: 0; border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center; width: 32%; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Trading
    Symbol(s)</FONT></TD>
    <TD STYLE="padding: 0; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center; width: 2%; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="padding: 0; border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center; width: 32%; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Name
    of each exchange <BR>
on which registered</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="padding: 0; font: 10pt Times New Roman, Times, Serif; text-align: center; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Common
    stock, $0.001 par value</FONT></TD>
    <TD STYLE="padding: 0; font: 10pt Times New Roman, Times, Serif; text-align: center; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="padding: 0; font: 10pt Times New Roman, Times, Serif; text-align: center; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">CTXR</FONT></TD>
    <TD STYLE="padding: 0; font: 10pt Times New Roman, Times, Serif; text-align: center; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="padding: 0; font: 10pt Times New Roman, Times, Serif; text-align: center; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
    Nasdaq Capital Market</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: White">
    <TD STYLE="padding: 0; font: 10pt Times New Roman, Times, Serif; text-align: center; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Warrants
    to purchase common stock</FONT></TD>
    <TD STYLE="padding: 0; font: 10pt Times New Roman, Times, Serif; text-align: center; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="padding: 0; font: 10pt Times New Roman, Times, Serif; text-align: center; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">CTXRW</FONT></TD>
    <TD STYLE="padding: 0; font: 10pt Times New Roman, Times, Serif; text-align: center; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="padding: 0; font: 10pt Times New Roman, Times, Serif; text-align: center; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
    Nasdaq Capital Market </FONT></TD></TR>
</TABLE>
<P STYLE="text-indent: 0; font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; text-indent: 0; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Indicate
by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (&sect;230.405
of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (&sect;240.12b-2 of this chapter).</FONT></P>

<P STYLE="text-indent: 0; font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="text-indent: 0; font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Emerging
growth company &#9744;<FONT STYLE="font: 10pt Times New Roman, Times, Serif"></FONT></FONT></P>

<P STYLE="text-indent: 0; font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="text-align: justify; text-indent: 0; font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for
complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. &#9744;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0; margin: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"></FONT></P>

<!-- Field: Rule-Page --><DIV STYLE="margin-top: 0; margin-bottom: 0; width: 100%"><DIV STYLE="font-size: 1pt; border-top: Black 1pt solid; border-bottom: Black 2pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="text-indent: 0; font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="text-indent: 0; font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Item
8.01. Other Events.</B></FONT></P>

<P STYLE="text-indent: 0; font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
October 25, 2020, we provided a letter to our shareholders to update them on our development program. A copy of the letter is
attached hereto as Exhibit 99.1 and incorporated herein by reference.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="text-indent: 0; font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Item
9.01. Financial Statements and Exhibits.</B></FONT></P>

<P STYLE="text-indent: 0; font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="width: 0.25in">&nbsp;</TD>
    <TD STYLE="padding: 0; font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(d)</FONT></TD>
    <TD STYLE="padding: 0; font: 10pt Times New Roman, Times, Serif; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Exhibits</FONT></TD></TR>
</TABLE>
<P STYLE="text-indent: 0; font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; padding-top: 0; padding-right: 0; padding-left: 0; width: 9%; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Exhibit
    No.</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0 0 1.5pt; width: 1%; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; padding-top: 0; padding-right: 0; padding-left: 0; width: 90%; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Description</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="padding: 0; font: 10pt Times New Roman, Times, Serif; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="padding: 0; font: 10pt Times New Roman, Times, Serif; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="padding: 0; font: 10pt Times New Roman, Times, Serif; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="padding: 0; font: 10pt Times New Roman, Times, Serif; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">99.1</FONT></TD>
    <TD STYLE="padding: 0; font: 10pt Times New Roman, Times, Serif; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="padding: 0; font: 10pt Times New Roman, Times, Serif; text-indent: 0"><A HREF="ea128836ex99-1_citiuspharma.htm"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Letter to Shareholders October 2020.</FONT></A></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 2; Options: NewSection; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->1<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="text-indent: 0; font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;</FONT></P>

<P STYLE="text-indent: 0; font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>SIGNATURE</B></FONT></P>

<P STYLE="text-indent: 0; font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pursuant
to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf
by the undersigned hereunto duly authorized.</FONT></P>

<P STYLE="text-indent: 0; font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="width: 5%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="padding: 0; font: 10pt Times New Roman, Times, Serif; width: 55%; text-indent: 0"></TD>
    <TD STYLE="padding: 0; font: 10pt Times New Roman, Times, Serif; width: 40%; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>CITIUS
    PHARMACEUTICALS, INC.</B>&nbsp;</FONT></TD>
    </TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="padding: 0; font: 10pt Times New Roman, Times, Serif; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="padding: 0; font: 10pt Times New Roman, Times, Serif; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    </TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Date:</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0 0 1.5pt; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">October
    26, 2020</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; padding: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">/s/
    Myron Holubiak</FONT></TD>
    </TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="padding: 0; font: 10pt Times New Roman, Times, Serif; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="padding: 0; font: 10pt Times New Roman, Times, Serif; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Myron
    Holubiak </FONT></TD>
    </TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="padding: 0; font: 10pt Times New Roman, Times, Serif; text-indent: 0"></TD>
    <TD STYLE="padding: 0; font: 10pt Times New Roman, Times, Serif; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">President
    and Chief Executive Officer&nbsp;</FONT></TD>
    </TR>
</TABLE>
<P STYLE="text-indent: 0; font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0; margin: 0; text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2</FONT></P>

<!-- Field: Rule-Page --><DIV STYLE="margin-top: 0; margin-bottom: 0; width: 100%"><DIV STYLE="font-size: 1pt; border-top: Black 1.5pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0; text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"></FONT></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>ea128836ex99-1_citiuspharma.htm
<DESCRIPTION>LETTER TO SHAREHOLDERS OCTOBER 2020
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><B>Exhibit 99.1</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: left; width: 50%; vertical-align: middle">
        <IMG SRC="ex99-1_001.jpg" ALT=""><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B></B></P>
       </TD>
    <TD STYLE="text-align: right; width: 50%; vertical-align: bottom">
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">(908) 967-6677 x105</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">ascott@citiuspharma.com</P></TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>LETTER TO SHAREHOLDERS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: right; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 5in">October 2020</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Dear Fellow Shareholders,</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Citius Pharmaceuticals, Inc. (&ldquo;Company&rdquo;)
has made considerable progress in 2020 with recent developments designed to contribute to increased value for our shareholders.
Additionally, there are many upcoming milestones that could be catalysts for further acceleration to corporate advancement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Our <B>Mino-Lok</B> product, which is a
project with MD Anderson Cancer Center that is in Phase 3, is in our opinion well positioned for entry into a $1.5 billion market
and has the potential to save the lives of many critical care patients. Our second project with MD Anderson Cancer Center is the
development of <B>Mino-Wrap</B>, which is a novel approach to dramatically reduce the rate of infection in post-mastectomy patients
who elect to undergo reconstructive breast surgery. We believe that this serious condition affects about 100,000 women in the U.S.
and many more in the rest of the world.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Our <B>Halo-Lido</B> product has an addressable
market of more than $2 billion. Based on National Institutes of Health reports, hemorrhoids affect approximately 12.5 million adults
in the U.S. (approximately 5% of the adult U.S. population). Halo-Lido could be the first prescription medication approved by FDA
for hemorrhoids and is moving toward its Phase 2b trial.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We recently executed our option from Novellus
Therapeutics Limited and licensed a very significant cellular therapy to treat acute respiratory distress syndrome (ARDS). ARDS
is devastating in its own right but it is also a major complication of the SARS-CoV-2 viral infection (COVID-19) and has led to
the majority of COVID-19 patient deaths. Combined, all these positive events demonstrate the value creation we are building for
shareholders.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">While the COVID-19 pandemic has affected
the patient recruitment in almost all clinical trials, including our own, the Company continues to make progress. Recently we had
our second interim analysis and report from the independent Drug Monitoring Committee (DMC) for the Mino-Lok pivotal Phase 3 trial.
We will soon reach the 75% point (event-based end point) in the trial, when the DMC and the Company could decide to stop the trial
and file the NDA (New Drug Application). For Mino-Wrap, we have submitted a pre-investigational new drug (PIND) consultation request,
have been issued an IND (Investigational New Drug) number, and expect a written response and guidance from the FDA in November
2020. For Halo-Lido, we have completed our patient survey to develop a patient reported outcome (PRO) instrument and plan to initiate
a Phase 2b trial in the first quarter of 2021.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="text-align: center; width: 15%; vertical-align: middle"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Citius Drug Pipeline</B></P></TD><TD STYLE="vertical-align: middle; width: 85%; text-align: center">&nbsp;<IMG SRC="ex99-1_002.jpg" ALT=""></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 49%; text-align: justify"><FONT STYLE="font-size: 10pt">11 Commerce Drive</FONT></TD>
    <TD STYLE="width: 51%; text-align: right"><FONT STYLE="font-size: 10pt">www.citiuspharma.com</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-size: 10pt">First Floor</FONT></TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-size: 10pt">Cranford, NJ 07016</FONT></TD>
    <TD>&nbsp;</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>


<!-- Field: Page; Sequence: 1; Options: NewSection; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: left; width: 50%; vertical-align: middle">
        <IMG SRC="ex99-1_001.jpg" ALT=""><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B></B></P>
       </TD>
    <TD STYLE="text-align: right; width: 50%; vertical-align: bottom">
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">(908) 967-6677 x105</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">ascott@citiuspharma.com</P></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I><U>Stem-Cell Therapy for ARDS Due
to COVID-19 &mdash; We Licensed a Promising Novel Therapy from Novellus Therapeutics Limited</U></I></B></P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On October 7, we announced that we signed
an exclusive worldwide licensing agreement with Novellus Therapeutics Limited, to in-license second-generation cellular therapy
for acute inflammatory respiratory conditions including COVID-related acute respiratory distress syndrome (ARDS).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">This technology is based on a unique and
patented approach of engineering mesenchymal stem cells (MSCs) from an induced pluripotent stem cell (iPSC) bank. We call these
cells <B>induced</B> mesenchymal stem cells (<B><I>i</I></B>MSCs). The starting point in this semi-synthetic process is a patented,
non-immunogenic, mRNA gene programming and editing procedure to create mutation-free, extensively characterized iPSCs that provide
an unlimited source of pristine MSCs. Currently, donor-derived MSCs are sourced from human bone marrow, adipose tissue, placenta,
umbilical tissue, etc. and have significant challenges; e.g., variable donor and tissue sources, limited supply, low potency, and
inefficient and expensive manufacturing processes. Our <I>i</I>MSCs overcome these challenges because they:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="text-align: justify; width: 0.25in"></TD><TD STYLE="text-align: justify; font-family: Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#9679;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">Are more potent and secrete exponentially
higher levels of immunomodulatory proteins;</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="text-align: justify; width: 0.25in"></TD><TD STYLE="text-align: justify; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#9679;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">Have
                                         practically unlimited supply for high doses and repeat doses;</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="text-align: justify; width: 0.25in"></TD><TD STYLE="text-align: justify; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#9679;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">Are
                                         from a single donor and clonal, so they are economically produced at scale with consistent
                                         quality and potency, as well as being footprint-free (compared to viral reprogramming
                                         methods); and,</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="text-align: justify; width: 0.25in"></TD><TD STYLE="text-align: justify; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#9679;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">Have
                                         significantly higher expansion capability.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">ARDS patients experience widespread inflammation
in the lungs and symptoms of shortness of breath, rapid breathing and heart rate, chest pain (especially while inhaling), and bluish
skin coloration. As you may know, ARDS is the most common cause of respiratory failure and mortality in COVID-19 patients, with
a 30-50% mortality rate. The pandemic has increased the ARDS population well beyond the baseline of 200,000 patients. There is
no currently approved drug therapy available, and mechanical ventilation and supportive care measures are typically used in the
most difficult cases of COVID-related ARDS.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We are currently conducting a proof-of-concept
large-animal ARDS study with promising results thus far. We have submitted a PIND to the FDA and have received their guidance and
feedback to our development plans.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><B><I><U>Mino-Lok&reg; (FDA Phase III)
&mdash; Interim Data Analysis Update </U></I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">Mino-Lok<SUP>&reg;</SUP>,
our lead product, is an antibiotic lock solution for use in treating catheter-related bloodstream infections (CRBSIs). We recently
held an independent Data Monitoring Committee (DMC) meeting to review data and evaluate the progress of the trial. The DMC reported
to the Company that there were no safety concerns, and all the endpoints were being met to continue with the trial. Following
the ad-hoc meeting, the DMC recommended that another interim analysis was warranted, and encouraged us to determine if the trial
will meet the interim superiority threshold at 69 events, and therefore be able to be halted earlier than anticipated. It is difficult
to predict the further impact of the pandemic on the recruitment of patients in the trial; however, we expect that the trial will
make significant progress through the first half of 2021. </FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><IMG SRC="ex99-1_003.jpg" ALT=""></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The antibiotic lock therapy is greater
than a $750 million annual market in the U.S. and is expected to reach $1.84 billion worldwide by 2028. We also believe Mino-Lok
may help eliminate as many as 500,000 procedures each year to remove and replace infected central venous catheters (CVCs), reducing
patient discomfort and saving large amounts of money throughout the healthcare system. We are not aware of any competitive products
in development to treat and salvage indwelling, infected CVCs. Our company has worldwide rights to this technology and will have
more than 10 years of exclusivity at the time of anticipated launch, which is estimated to be in 2022.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I></I></B></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 49%; text-align: justify"><FONT STYLE="font-size: 10pt">11 Commerce Drive</FONT></TD>
    <TD STYLE="width: 51%; text-align: right"><FONT STYLE="font-size: 10pt">www.citiuspharma.com</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-size: 10pt">First Floor</FONT></TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-size: 10pt">Cranford, NJ 07016</FONT></TD>
    <TD>&nbsp;</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>


<!-- Field: Page; Sequence: 2; Options: NewSection; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; margin: 0pt 0"></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: left; width: 50%; vertical-align: middle">
        <IMG SRC="ex99-1_001.jpg" ALT=""><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B></B></P>
       </TD>
    <TD STYLE="text-align: right; width: 50%; vertical-align: bottom">
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">(908) 967-6677 x105</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">ascott@citiuspharma.com</P></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<P STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B><I><U>Mino-Wrap
&mdash; Post-Mastectomy Infection Prevention, a $400 Million Market Opportunity</U></I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Mino-Wrap is a bio-absorbable, antimicrobial
semi-solid gel that is wrapped around a tissue expander and placed in the surgical pocket following a mastectomy to prevent post-surgical
infections. Once installed, Mino-Wrap slowly liquefies <I>in situ</I> for a specified period of time, providing extended protection
against infection.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The reported rate of tissue expander-related
infections is between 2.5% and 24%, depending on the extent of surgery, duration of post-operative drainage, and many other factors.
Once the tissue expander becomes infected, the patient is hospitalized and the tissue expander may need to be removed. These serious
infections may lead to a delay in life-saving chemo-radiation therapy, which can be a devastating consequence for the patient,
and can also lead to a delay in permanent breast implantation. The market for Mino-Wrap in preventing infections following breast
implant surgeries following mastectomies is estimated to be $400 million.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We&rsquo;ve submitted a
pre-investigational new drug (PIND) consultation request with the FDA. They assigned an IND number, which is a positive sign.
The next step is for us to receive written comments from the FDA in November 2020, in which they will respond to our
questions and provide direction about the clinical development program that we submitted.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Mino-Wrap is designed to allow the temporary
tissue expander to be inflated without any restrictions and to prevent infection and biofilm formation surrounding the tissue expander
over a longer duration than that from the current treatment regimen. Mino-Wrap could also be used with breast implants during reconstruction
following removal of the tissue expander.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I><U>Halo-Lido &mdash; Aiming to Be
the First FDA-Approved Prescription Product to Treat Hemorrhoids in the U.S.</U></I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Halo-Lido is targeted to the symptomatic
relief of hemorrhoidal symptoms and combines the high-potency steroid halobetasol with lidocaine. Based on results of previous
clinical work, we selected a gel formulation combining the potent steroid halobetasol propionate and lidocaine HCl to move forward
in clinical development. The manufacturing scale-up is complete and the formulation has met chemical, physical, and stability criteria.
This formulation will be used in a Phase 2b study expected to start in the first quarter of 2021.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Most importantly, we have just completed
a rigorous study of the severity and impact of symptoms of Grade 2 and 3 hemorrhoids in order to create a patient reported outcome
(PRO) instrument. We are preparing for our Phase 2b trial to test our new formulation and validate the PRO. This innovative trial
will use hand-held devices specifically programmed to record patient diaries in electronic form, which should improve the quality
of the data and the speed with which they are processed.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Over 10 million patients in the U.S. admit
to symptoms of hemorrhoidal disease, and one-third of them seek physician treatment, yet there are no FDA-approved prescription
products available. Over-the-counter hemorrhoid product sales are approximately 20 million units annually, equivalent to an annual
$2 billion market. Our formulation, if approved, would be the first prescription product to treat hemorrhoids approved by the FDA
in the U.S.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">While there are some commonly used prescription
products, none have been reviewed or approved by the FDA because they entered the market prior to 1962, and are considered Drug
Efficacy Study Implementation (DESI) products and are allowed on the market without modern review. We anticipate that these DESI
products may have to be withdrawn when an evidence-based trial is conducted and should FDA approval be granted.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 49%; text-align: justify"><FONT STYLE="font-size: 10pt">11 Commerce Drive</FONT></TD>
    <TD STYLE="width: 51%; text-align: right"><FONT STYLE="font-size: 10pt">www.citiuspharma.com</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-size: 10pt">First Floor</FONT></TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-size: 10pt">Cranford, NJ 07016</FONT></TD>
    <TD>&nbsp;</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 3; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: left; width: 50%; vertical-align: middle">
        <IMG SRC="ex99-1_001.jpg" ALT=""><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B></B></P>
       </TD>
    <TD STYLE="text-align: right; width: 50%; vertical-align: bottom">
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">(908) 967-6677 x105</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">ascott@citiuspharma.com</P></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I><U>Looking Forward </U></I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The remainder of 2020 should be an exciting
time for all Citius shareholders given the numerous milestones ahead across our full pipeline of products:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="text-align: justify; width: 0.25in"></TD><TD STYLE="text-align: justify; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#9679;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">For
                                         Mino-Lok, we expect that the trial will continue as planned until it is fully enrolled,
                                         which we expect to be in the first half of 2021, given the continuing impact of the COVID-19
                                         pandemic on clinical trials. The antibiotic lock solution market is estimated to be a
                                         $750 million opportunity in the U.S. and is expected to grow to $1.84 billion worldwide
                                         by 2028.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="text-align: justify; width: 0.25in"></TD><TD STYLE="text-align: justify; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#9679;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">We
                                         have licensed an exciting new cellular therapy and hope to become a leader in next-generation
                                         stem cells for the treatment of COVID-related ARDS and other acute respiratory indications.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="text-align: justify; width: 0.25in"></TD><TD STYLE="text-align: justify; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#9679;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">For
                                         Mino-Wrap, we are making progress as planned and the next step is for us to have a call
                                         with the FDA in November to discuss our preclinical submission as we hope to initiate
                                         a Phase 2 trial by the end of 2021. </FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="text-align: justify; width: 0.25in"></TD><TD STYLE="text-align: justify; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#9679;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">For Halo-Lido, we have just completed the development of a proprietary
PRO, which will be used to measure the improvement in symptomatology for Grade 2 and 3 hemorrhoids. We are getting ready for our
Phase 2b trial and expect to initiate this Phase 2b trial in the first quarter of 2021. Halo-Lido would be the first FDA-approved
prescription product for symptomatic relief of hemorrhoids.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On behalf of the Citius Pharmaceuticals
team, thank you for your interest in our Company. We look forward to sharing future important corporate developments and our clinical
progress with you. In this current healthcare crisis, we hope you and your family stay healthy and safe.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Sincerely,</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><IMG SRC="ex99-1_004.jpg" ALT=""></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Myron Holubiak</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Chief Executive Officer, President, and
Director</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><IMG SRC="ex99-1_005.jpg" ALT=""></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Leonard Mazur</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Chairman of the Board</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Safe Harbor</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">This communication may contain &ldquo;forward-looking
statements&rdquo; within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act
of 1934. Such statements are made based on our expectations and beliefs concerning future events impacting Citius. You can identify
these statements by the fact that they use words such as &ldquo;will,&rdquo; &ldquo;anticipate,&rdquo; &ldquo;estimate,&rdquo;
&ldquo;expect,&rdquo; &ldquo;should,&rdquo; and &ldquo;may,&rdquo; and other words and terms of similar meaning or use of future
dates. Forward-looking statements are based on management&rsquo;s current expectations and are subject to risks and uncertainties
that could negatively affect our business, operating results, financial condition, and stock price. Factors that could cause actual
results to differ materially from those currently anticipated are: risks associated with conducting our Phase 3 trial for Mino-Lok&reg;,
including completing patient enrollment, opening study sites, and achieving the required number of catheter failure events; risks
associated with developing Mino-Wrap&trade; and our planned ARDS therapy, including that preclinical results may not be predictive
of clinical results and our ability to file an IND; the estimated markets for our product candidates and the acceptance thereof
by any market; our need for substantial additional funds; risks related to our growth strategy; our ability to identify, acquire,
close, and integrate product candidates and companies successfully and on a timely basis; risks relating to the results of research
and development activities; uncertainties relating to preclinical and clinical testing; the early stage of products under development;
our ability to obtain, perform under, and maintain financing and strategic agreements and relationships; our ability to attract,
integrate, and retain key personnel; government regulation; patent and intellectual property matters; competition; as well as other
risks described in our SEC filings. We expressly disclaim any obligation or undertaking to release publicly any updates or revisions
to any forward-looking statements contained herein to reflect any change in our expectations or any changes in events, conditions,
or circumstances on which any such statement is based, except as required by law.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 49%; text-align: justify"><FONT STYLE="font-size: 10pt">11 Commerce Drive</FONT></TD>
    <TD STYLE="width: 51%; text-align: right"><FONT STYLE="font-size: 10pt">www.citiuspharma.com</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-size: 10pt">First Floor</FONT></TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-size: 10pt">Cranford, NJ 07016</FONT></TD>
    <TD>&nbsp;</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">4</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Rule-Page --><DIV STYLE="margin-top: 0; margin-bottom: 0; width: 100%"><DIV STYLE="font-size: 1pt; border-top: Black 1.5pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>ex99-1_001.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 ex99-1_001.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1" !# .(# 2(  A$! Q$!_\0
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M(BZ"5D:18RP\QD0JKN$SN**SHK,!A2Z@D%AE] !1110 4444 %%%% !1110
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M_@IUXQ\6Q_&J?Q?;>&D^&?Q#U?5)+"3P9'H4NIG5UUWP9H+0I.NOV?V-[<7
ME:.X5_+,8W>?RZM75[VZZ_@>OS:7L[?+O8_TW**_E:_X)4?L6_\ !>#P+^T5
M\$OCY^V7_P %"M,^-W[+NJ>!M4\1^)/A8WC?Q'X@U+6QXR\!SR^#XI=,O_ F
MD:<+K2-9U33-2GN4UA1;FPD$#W D"2?#'_!&']NG]L7XT_\ !P)^W#\ /BS^
MTC\6/B%\%/"%O^U8WACX8>*?$TVI>#= /@OXT>&="\)?V1HKQK:Z<?#VC7=S
MIFG&S6%EM)I$G,[,7*MOJG97T#FVNFKOR\M?Q/[C**_AZ_9__;G_ &P_$/\
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M#\:?![QIXC\#:MXI^*'AFU_M[PWJ=SH^IMHEYX2\4:RMH]Q:E9C!<2VMG)+
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MK3Z*GBK4K+2X/%'C/Q#-)?VQ@TRWCDBN]36=M-L](TZ6>.G_ ,%?[+QWJ/\
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F1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% '_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>4
<FILENAME>ex99-1_002.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 ex99-1_002.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1" #V ?@# 2(  A$! Q$!_\0
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M^$^J^'4N?[.\P6O@C3XEUG1M4\O[1J<Y?3[BVLK<^:_HNC_\%3]8\-:+\'-
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M5*=2G.$X3C&4)PE&48RBTO&Z_1G]@WX7?!;QMX5_:2\;?&C0_A7J6E_"VU^
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MA0?#64_&+5?A%IO[%WAK]IU/"&F:1%XV;P]JGB>6TUI-'L_"-O:I;GQ$;OQ
M/$\^F*=(K\C[_P",'Q<U7^U/[3^*/Q"U'^W%\5)K7V_QGXDNSK">.K?3;3QN
MNJ_:-3D74%\86NC:/;>)UNUE77+?2M-AU(7$=E;K'-%\:OC+!>:5J,'Q;^)<
M&HZ'K6G^)-&OX/'/B>&\TGQ#I7AVW\'Z9KFFW$6JI+8ZMI_A&TM/"MGJ%JT-
MS!X;MH=$20:;&MN,(9%G].G2IPSN*]E9IRISFKJ'Q<U3FK>T<YU+SG.K%1M:
ME)QBI>IBO$?PRQF/Q6+K^'$VL6\1"M*EB\'AZTJ&)Q#DZ2AAU1PE.G2PRI^S
MI4,/0F\3"I?&TJ5>3H?HGX%_X)[>&O$GPG\0?'6VUCXN^'-)\/6]Q\1?!GA?
MXO\ @7X?^%W^(7PY\,?$CP3X.UNPU'PSIGQ"UOQUI=_<MXDNK>3Q ?#X\'27
M5K%9V]S<1:A%<#Y(_;C\(^&/ /[9'[3O@CP5H>G^&?"/A3XT^.-#\.>'-(MH
M[/2M#TBPU1X;/3--M(OW=M96L0"001X1%X4 &O+[GX]_'6\TK6M"N_C5\6KK
M1/$FHWFK^(=%N?B/XSN-(UW5-1N(;O4-2UC3IM;DM-2OKV\MK>[NKF[BEDFN
M8(9I"TL:N//=<UW6_$^LZIXC\2ZSJOB+Q#K=[/J6M:]KFH76JZSK&I73^9=:
MAJFI7LLUY?7MS(3)/<W,TDTKG+N37J9;E^;4,=5Q68YC'%4GAZE"A0A[1*G>
MKAY)RYHP565J<W[2=.,ES24;1DX+X_BOBC@K,>'<%D_#'"M;)<;#&X3'9EF5
M>I@9O&U:&%S/#58T:=!XBIA:-3Z[0<:%+%>QDL-2E7A6Q%&.(GE5[+X0_P"2
M'_'7_L8_@7_Z=/B)7C5>R^$/^2'_ !U_[&/X%_\ IT^(E>EC_P"#3_["\'_Z
MDP/C<@_WO&?]B+B'_P!4]8\:HHHKLC\,?1?DCQ'N_5_FST'X1Z%IGBCXM?"G
MPOK=JU]HOB;XG?#[P[K-DDLL+WND:YXOT;2]3M$F@>.>)[JQNYX%D@DCF1I
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MX%^(6IV]M^RY\5_VDK'X#?$#3?#?BGPU^SE'I7P9\2>,-7^/7AS4_A;H>E>
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M0**_;_\ X4=^QY_T; /_  ^WQA_^7%'_  H[]CS_ *-@'_A]OC#_ /+BM_\
MBIU]$S_HI.-/_%?9Y_\ -QP?\4P_I+]_#S_Q,X?_ #B/Q HK]O\ _A1W['G_
M $; /_#[?&'_ .7%'_"COV//^C8!_P"'V^,/_P N*/\ BIU]$S_HI.-/_%?9
MY_\ -P?\4P_I+]_#S_Q,X?\ SB/Q HK]O_\ A1W['G_1L _\/M\8?_EQ1_PH
M[]CS_HV ?^'V^,/_ ,N*/^*G7T3/^BDXT_\ %?9Y_P#-P?\ %,/Z2_?P\_\
M$SA_\XC\0**_;_\ X4=^QY_T; /_  ^WQA_^7%'_  H[]CS_ *-@'_A]OC#_
M /+BC_BIU]$S_HI.-/\ Q7V>?_-P?\4P_I+]_#S_ ,3.'_SB/RA\"8_X5-^T
M."<'^P_A00.Y'_"V?#P) ZG')/TKQ\]3]3_.OW:T[X8?LH:5HOB;0++]F2%-
M-\86VD6>O))\</BY++/;Z%K%MKVFK;2OJADM7AU2T@FD>)P9H@\#85V-8?\
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MF^5U,-B:.2>QKQA.].IR-3I5$XU80;@Y_P ?.1ZC\Q17]@O_  ZM_P""<?\
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MU*+]D'Q+INK7NH:4\S7OARY@\/VYO]=MI=%B[[XB?LY?\%.=.\&:GX#L[/\
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M1RSA6BLGC4Q1.WF.N1MR:_7)>H^H_G7Y*_$GQI+\._VN?B1XVM]/BU6?P_\
M%#QK<Q:?/.]M#<O=)JFF!9)XDEDC2-;\S$K&Q9HE3@,6'^?7[0>.42X2\'HY
M_*<,BEXIS6<RI.LJD<J?#;6/E3>'C/$*:PKJN#H0G54E'V<7*R/W#P-^MK->
M*G@$GCEPU?!*7+RO%K'S>'4^=J'*ZJBFI>Z[VE9-M<7X;_9W^+_B2^\)VL7A
M"ZTFU\:'26T36-;N+*RTIK?7M.N]5T*]NY5N9;FTL]:L;&[ETF6:U4ZBT$L-
MFL]PCPKS4?PA^)LUK!>P>"]7N;6ZO[;3;:6S?3KW[3=7FLIX<M'MH[2^GEN=
M/NO$,B:';ZU DFAS:HZV::D9LJ/5/#O[2NH^'M?37H_!^F7CC0_@AH3VTVJ7
M2J;7X*:?_9UK*LOV5F$_B.W:7SSMVZ0\K-;_ &T91G:5^T?)H=IX-L]'\,ZK
M86W@5/#FDZ190^-9%TS4/"GACQG%XQT_1/$=G'X9CNM6N'E1M/N[NWU/3=.N
M2EGJK:"M]:@2?YH1R;P$K8:ES<4\48:O&I45:7L*<ZM2+GE=%2C1>2+"1I4Z
M4\SS&G"-5XBK4IK+93YY8;%R_H.>+X]A5FUE>6UH.,73A&K[.G%*&+G*,JD,
M>ZSK2:PF';Y9TOCKPCSU'3CQ;_ +XHH8]/7PAKTWB=+SQ#%J7AU;.R1-(T[P
MU9Z->ZKJ5[KG]K2:6ATY=;MDUBRF>WN-$1K:2_D'VDI#RWB_X5_$;P#!;W7C
M3P=K'AFUN[]M+@GU1+:.,ZB(/M264S1W,IM)I[(B_M#>"!+[3C_:-DUS99G'
M:6GQNO;7PAXR\(KX=L&M_&7_  MO[5>B]N5EM!\69?!<U\(X?)V3_P!C-X+M
MQ TLJMJ":A,MQY'D*),[QO\ %ZZ\;67B>RN-"M+!/$GB_P $^+I6BOKF?R9?
M!7@";P!;V!S%!)-!?V4IOGG,L<MM.%MXU9%6<>7FN!\&O['K5<HSGB%9VL%*
M>$PV(I4G@XXJE5JJCA\7/^R5.O+$4(4Y8K%8>MA::K8E.CAZ4,(X8CKP];C%
M8N$,5A,#+!+$4XU:D)-594)MN<J/+B[4Z=)SM&E5A4KRC1C&IB'&JYQE\6_!
M'Q'X:\5#P-8W]EXE\6VULUUK6E65M?Z+:Z9;F.P-M?V>N^*HM%T7Q#I&I37\
M5OINJZ)>7-K?2J3;>9#+;2S;5S^SMXUM? OA_P 2MI^K3>)O$6K^+[(>$Q:Z
M/:Q>'--\#ZC%H^NZCXLUC4?$-D^BW"ZG(T$%K<:6MG&1%;7FIP:A=6=I<;^D
M?M$Z1HVD:9X=M_AHMSH.D#5YM(36O&EWXC\0>%[C69-",UGX'\1:[H%Z/#&A
M16VB26@TP:5J%PPUK4[N+4[:^,5P-'4_VJ]5U:]UJ2?P=:VNG^(Y?B.VK6VG
MZVT>HK'\0O'>A?$ #3M2O='U"VMI-!U7P_:6B->:7J4.K6,UT+FWMY3#)']3
M2RWZ/E\PQ.)S['PJ9A1>&P.68*CG=>CD$IPR^I&O]?QN64UFF+H5*&*P<L?4
MIT\OKPQU;'_V11J8"."K^7/$>(#]C2A@:?)AYJK6Q-2K@*=3'KFQ<'3EA\/B
M)K"TW&6'K/"TJDJL986-&&8U*6+E6/+M:^!7Q,\/^&+7Q5J?AQX;&5/%LVH6
M1N[-=;\/VG@J[MK/7K[7=&>X2^M;2U>ZCF,T$5T([96N+D00O \V]\//@#XA
M\:7NI:5K%RW@W4Q>^!=!\/Q:Q8S3Q:GXD^(-K-KVAVMXMF\EW!9_\(78:KXH
MF-K;W&H"&/3+<VB-?$KUWASX]Z/J_C+X>7/CO2+]])T'QKXONO$.NZIX@U/Q
M'=ZM\.OB%8PZ=XR\'ZY86VE6MSKES>:3:)I=AK$$EBT DM]VFQK;BX@IS_M$
M"U\3_#SQAINDSZAJ&A^/_%_Q7\8:;?3C3;?5/%7B*630]$T6QOK4W[QZ7X1\
M!66DZ+IE\("T=Q-J/E6BQD/+&$RCP*PN)PN=2SG'XW)Z6+P.6XG(\PQ$IXW$
M4Z^'RVAC\WD\)E^!QD(X6KF&.QD,/@XU:,:N4-T*N(PM6.#D5<;QU5IUL#]3
MH4,=*C4Q5+'8:GRTJ/[W%5*&%Y*U>OAVZBPU*@JE1N5L7&-:%-TJE1:'P\_9
M:O/'R+/!XNEL[:Z\9Z%X(TZ6X\(WFCW+:IJFB:KK]]<ZGHGBW6_#>NV6F6&F
MZ8JVLUI8ZC/J]_?6ZVMNNGP7][;^;:Q\$O%YU-X/!NB^)?$^F#1-/\0-?7NB
MV'A^2&TU6ZUFWL+=0?$.K:;JMQ<_V%J)L?[#U;47U7['>-IUO/':R2-O>%/C
MM#X*N-&;0_"M]>V^D?$C0OB4#XJ\7W/B#5+G4=%\(^)/"/\ 9<FJC1-/9=.D
MM?$7VF%A;-+;260B3?'<NT5>[^-]EK?@/P]\._%?@.VUWP_X7TGP;;Z6MMXD
MO]"N6UKP9:>+-/L]4O+FSL+F:6QU"P\5RQ7VCPM;2P36$$^GZO;M<7&<\9'P
M*QN1T<#2E+*<[H8>K7JYAA9YS7I8_'1>)E1P/UNOE^*HX'+Y^TI>TQ-/*,=6
M_P!EIX=1C]:>*I;4WQS0QM6O)/&X.<XTZ>'JPR^E/#T9*//75"E7HNO6C*$8
M1A4QM*FE4JU97<5"7%K\'_B<\FFQQ>#=3F.KQ:E/82PS:;-:-#H]A:ZKJS7M
M]#?26.CMIFFWMI?ZA%K-SI\]E:W,$MS%$)4W4-8^&GC[P]<:C::WX2U?3+C2
M= 'BG45NHX EIX=.K+H*ZQ+-%<20FQ?6G73(GCD>26\98HXG)Y]ZU/\ :?L=
M4\,W'@G_ (5;I>F^$M63Q#!KNC:1XA;3;=;#Q!H/AO2?[-\+"R\/P)X=M=)O
M/"NF:M8F]A\1W%S))>VFK7&H17)E3C]?^*^BW?P0A^'VA:='I&J7WCW59FMC
M-J&J7'A[X7V$EKXA\/\ A&37=06 :S%<^.]0U?Q%NBACFA>T4744,4]K;IY6
M9\,^#=/#X^>3<:YGF53!9)B,QBZF%C@O;YKAZ="G1R?#X?%Y30=:CF%?%T)T
M<>\5]9PKP^/PF)RV5.DLTAMALQXQ=3#T\;E.&PRQ.,I4-*BK>QPLIXEU<7*I
M1QU6TZ5+#KGPGLI4VL3AJE/%N<Y8>GRD/P<\5W/PXT'XCVC6%[:^(_%]OX2T
M_P .VLLQ\2AK^ZO=*T;6VLY(UMVT/7O$>GW_ (9TN[6XWRZU931,BQ-$S,OO
M@A\5]-U>VT&_\#:Q8:O=PW<]O9WMQH]F95L-1M](OH$N[K4XM/74;+5;JVTZ
MYTF2Z35(+RYMX);-7FC#>@Z%^TMKFBWFF6O_  C6CW7@O1?"7@SPMIO@S;9V
MXAE\"ZKI'BC1]>?Q,FDMKDM^_C/3[[Q+/!)(]F)]9U&V2!(Y5E!X=_:)CT8R
MK?> -*UC?XN\?>,;6].J?9-4TB^\>>*?"WB>^@T>[NM%U:"R#+X9&B:A>K9?
MVC?Z9JEV+>ZTR=!+)K'*/ K$QRRG/BG/<!56&P&$S.L\#BGAI8S X?#/-LRB
MEEF98F.'SW$8O$1RM4&H97#*(RQ6 G#'234L5QY3^MVRS UX^TQ%?"1^L8=5
M8T<3.2P>$E-5\-3E5RVE3@\5*:J+%5,3)PJ\U!<W#>)/@SXOT/1/ NL6^F:K
MJ,OC")+2\TR/2WM[KPYXHO/&GBOP9I'A&_$TYFEUC4KSPCJ#0$P6\1G\RR*K
M+ &FCD^"?Q$T\ZO!KWA?7=(O].T:75K?34T^#5;^ZECU70M+CLKRUT[49+O1
M([B3Q!IS07FH69%RU[IZ6D$\=]%.ONNE?M1B^\2>(_%>NZ)I^FO:^ _':^%]
M&1[[5XM0^(^K_$G6/B/X#U<R-!&EA/X*U[Q+>W,5S=,+>YL-.EB9OM.H^0O!
M0_M!6UMX??0X_!5Q=75SX5F\)WWBK5/&$]WXSDTU]4\&:K;6EIXG@T.QU&#3
M-)N/"+2Z#9:@=7N]%N=7GDLM42UL[:S;T,3D'@1&<,;2XKS:&'Q-"K]5PLL)
M-17]ET:&6U95J$<#BL91Q>=XZK',\(L3B*&!P$<-F4L5]<PU3+*2YJ./X\<5
M2>4X252E*/M:OMXWB\14^M0@JCQ-*A6C@*2E@L1RT:M7$*5*,*E+$4\1*IY[
MHWPG\3W7Q%T+X<^(;=O"VI:K-))?7%TUGJ:Z-I-E!?WNL:I<1Z9?30S?V78:
M3JTTUD+N&X^T6,EI,;:0[ET-9^#NM:=;>"(["_CUSQ)\1-)TOQ'X6\*Z9HVO
MFZOO#VL6MU?VU[%KTU@OA:ZN=-LK97\36=IK,_\ PCMS)+:WUQNLKV2#MM"^
M,^A77QF\'^.M4T(^&M%M]$U3PAXMU*"6+7?$.KVOBC1/$?AS6_&GB"ZMM+TB
M/7?$L5GXC$L]U;Z9;75]:Z1:I.+[4'FNIF^ _P!H(?#+0H/#?AKP@LMI)<0#
M7#J/C#6M7TR5(]!UOPWJ]_X&TZ^TY6\!:CXLLM<N;W5;ZWDU20O':6AM6L(F
MLZXLNRGP:C1S&EF>=U(X&OG>:X7+\\C',L3G.#RO#PX8K9?4I9%A\)A*.-Q&
M*P^)SW#3Q6,^I8+#XW#5<;##X[#0HY?5VQ.+XP<L,\+A)/$T\#@J^*P%L+#!
M/$U89E'$1EF-;$594W2K4L'6EA:7UN=>C56%57!56L1'@;+X&?%_4I+Z.P^'
MVOW;:=-IMO=&#^SGA:;6K%M2T2*QNAJ'V35GUFR22?25TB>_;4O*DALEGG1H
MEH>(_AOJVBZ3H.O6$=YK6B:SX&TGQK=ZE'I\UJFAK?:]J/A/4=-U-)'<0MI7
MBG2KO1UN&DQ>.UJ_EP27 @7WK3_VA/#,7A&.ZUC0M<\3>)_#GQ4^'/B_P/HF
MO^,;Z6/2+?P%X:UV*TO)]8TWPUI^F3Z5_;=_!$_A2TL-((AN9YK"ZA(EF/FO
MCKQKX(\2^%/#]E,=8U3Q1H?@VUCLKNQB;2=$C\9>-/B!XH\>_$6\U"*XS-=V
M6E6^KVGAW1[&VA2VNM0DN=42\^R64"7DYOPMX48?(\=B,DXGEC<QEE-',L/1
MQ^9813HU)8_'0IX*G/#Y/A,.\95I8.K3JX&5#%8FMA)9=C75R/%8ZGARL'FO
M%5;'X6GC\M6&PZQ<L+6^JX:I4IS;PF&DZTY5<?*HZ$:E6=7V\)4*=&I&K1A'
M%TZ7++@[GX=>(H_^$&CLUM-3N_'_ (6?Q9H]G;W$5HUMI\&L>(='GBU"ZU26
MSL8;B)_#=[?2R?:1:I9O"1-YWF1C;LO@?\4[V_6P;PA?6!&O:9X;GO-5N-/T
M[3H-3U9=,FM56\N[R*/4+=;+6M)U.>ZTC^T((M-U"TO"YAN(&DZ/1/C!X?TV
M+P#/J?P]37=9\ >#=3\$Z?=W/B*W739K'4=2\2ZG%K4>BWOA?5(+7Q-I%QXH
MN)]&OYY]0L+2]L+.\ETNY8&,=AKO[3,.LWNMZC+X 2YGU"'PD-(T_7?%,^N^
M'] U'P=IGA72=+\36FDRZ';31^,%M/"X277]*U/0X[F/4IK6^TV\M+2UA'/@
M<B\&*E)XS-.+L=0J2JY;.EE67T<PDX86.0Y74S..,Q5?(*TOK53/*>:TJ%#+
MYR4:6)H1EB(PP_MY:8G&\:0J>RP>3TJD%"O&6+Q%;#RDZKS'&JA*CAZ>80A[
M%9;+ RFZZB_:4<1;]]6A%^9V7P>UH>,_'O@OQ#J^D>';KX<:!XI\1^)M2<76
MNV:Z;X3GMH+]M-BT%+NYOKBY%TDUE;[(YE1'CO8;:<&(:>M_L]?$[2/$=YH-
MMHT.MV]K>Z-;_P!O:9>VL>E&RU\:(VEZQ=6VHSV>N:9I+'Q%I,%_>:GI5K%I
M-]<-IU^T5W&8RRV^,LNB^/OB3X]\)Z'<>';[XBZ!XRTKR8O$-U<W'AO4?&]W
M;:CJ>LZ9JJV-E<2/;7\4\EE:F"%H[>=87NI&B,LO0>'/VAKOP_X-UOP\_A6#
M5/$.OV.MV6K>,KO67:]UN;6O%FC>*VUGQ+#-I4^IZ]K5E+HT&C6L]QXCBLTT
M8^6+!+T&[:\LP?@EB*-3 YIC\TR^O2S?BG&0SG"U\PQ,:V3X3,JL.&<HC1J9
M7+VV(S/+98>K+&/+\#*A*G7^LU*>*JPH49Q-3C>FZ>(PN'PM>,\+E6'G@JRP
M]*4,75PS_M7&N5+%_NZ.&Q7/&G36*KRK1]C[.E"FIUI>1^*O!.J>"/&^I^!?
M$]QIVGZCHNN/HVJ7T-TFHZ7;K%>-:S:D)[%IG>QC5'NG0HE_' C1SVD-T&A7
MT1/@/XDAO/B#9ZG=PV1^'WB2]\)3FRT^_P!:N/$.LVOASQ#XL:7P_9P-:O/I
M,'AOP[-X@O\ 4KF:%;#1;^QOI()VE6WDXKXB>+O#_C?7_$/B/3_",WAS4?$W
MBC6O$FJ;_$4VN6K_ -N2F\NK"V@DTS3C;QIJDU[>17#M--]FN8M/D$GV3[7<
M>E3_ +16M70\!+<>'=-<^#?"?B[P]JLJ7UU%+XTUGQ7X"?X;#QAK;>1(L.K:
M7X2MM$TN"")9HIDTEY#-$^HSB/S,JPWA71S?B.EFN/JULLH9HZO"^(P[S3$T
M\5E.-Q&99=3PN8K^SL#7=?)<+++>(<15E1HRQ\Z=7*J;J5)SMV8JIQ3+!9;4
MPM"*Q<\)R9G2G]4INCC*-'#8GVU!/$UZ<J>,K1Q&5JG&K-8>-9XYIJ$5'#T+
MX _$;6M031;C0KW0=;O)O"\&G66J1VOV4/XIUZQT"W;Q!J,&H,OA46MSJ%NQ
MAU2U-]=RNMC#8K=2Q@\1;_#CQI?>)-9\)Z=HCZCK?A\W#ZQ%9W^DR65C:V\\
M%J;VYUA]031H+62YN;:WADFU",R7-Q#:(INW-N/:8?VE#86MG#IG@.S>^A?P
M/-?^(=?\0SZUXGUU_ 7C[1?'6AP^(-:M](TF;6K6S_L9-!T]M0BGU6QTRXE>
M75]0:.WMX>+\+?%^W\(:W\1IM&\,W5KX7^)%G;V>HZ)%XC5M;TL6>OVOB2SG
MTWQ)=Z!>6LDD6J03B6*]\/303V-R;<QQW$,5X/0QV5^"W/D6&PG$>:NC/,*B
MSS'1PU=8FEEE3*L;B,+2ITJN4PPE3%4\XIX3 8[,\/"-*AAJZQ.$RW&4(/EY
M*&*XV=+&U*V7X:-3ZI#ZC1<Z3A]:IXZC2J5)SAC95E"I@ZDJ]'"3;E4E2J*M
MBJ4FHJ#P]\ /BOXBU?3-'3PK/HTVJZAJNEV\WB2[L-#CCO=%_M2/4HY[>^NH
MM1"6]YH^H:<+B&QFMI;^W>WCG8I*T? ^'_"&O>)/%VD^!]-LXY?$FM:U:>'[
M.R:]M&MUU2ZF6$I/J-M-<6"VUL?,DN;Z*XGM4MX9ITED1!N]WL?VD/LEU8:C
M>>#+GQ1JEAXO_P"$GAU'QIXSN/$=_96UQ)KBZOIOA_47\/VFIZ#+XAL]9%OK
MMU'>7FFW=Q80:A#H5O=S2RCR+0?&UEX)\9>$/&7@#P^VAW7A#4;;48;+6=9F
M\1VVIRV=_/-!'<O]ATJ2"UFTF2/1;ZVMU1IU$]]%-;33B.'SLVRSPEP[X=GE
M&?9EC*"SK"?ZT1Q4:[S%9#7EEU+$0RZC1R3"Y;6QN&A'-,2ZV'Q4&O;87#>Q
MKUZ,JTNC!XGB^4<Q6-P&&A66"K_V6Z4*7U9XZ"KRA]9E4S&K75&M*6'A3C.G
MS>[5G*="/+%=)-\(X);*/6-!^(G@GQ!X>MO%EKX*\0Z\H\0Z-8^&M7OK74;_
M $R\NX]7TBWO=2T+6K;2M332-3TBUNY+V[L/L(LHKJZM%N(/$/POTOPGKOB'
MPKXB^(/A[3-?\.?$+4/!5ZIT_6[S3DTO1-.N+O5?&$LEE:3:C;Z=)?"RTC1]
M._LR>_U:\N+G_CQBL)I6WA\3/AF/!^M^$;7X:>(=$L]6\::)XYE.G^/H=0>_
MN]"AU2UTSPW>W6J>%C-I_AS2(=8OKG3IK&*[U::\94U6:_A99+;%\0_$KPUX
MF^,.H?%'6?A^FIZ1K7B&Z\3Z]X"O?$MQ)IVIZC=237,MJ=8M](MKJ/1FO&@G
M;3GL;B2:VBDL;B\ECN'=>_-,/X84,'@9Y;6X;KYCCL=EE+&1>8<:ULLRO"8J
MGFU#,\5&E6RG#YE['+*F'R;%*,ZN+QN*GC\?'"TJ^'IX2GAL\+5XHJ5J\,53
MS2GAZ-#%3I3CA>'J>*Q-6BL'5PE+FCBZN&53%NKC\.Y*$*%%87 RQ'\3%U)Z
M2_ O5)-3\1V$'B_PA,FB?#!?BUILK2:S;77BGPO)X</BB%=)T>?35U*SOO[+
M5WO8]9CT^#3[C[/;M<7!O;9G\+_7_/X_S->_:9\9M&M/&?CCQIJ?A/Q!K]_X
MZ\(^)/"%\M[XWM;=[.S\6:3+HFJRVDEIX.CMHTL]-%E;>'=/@L+33=#@LDM4
MM[NV,4,'@;[-[^4K+%O;RT=@[I'N/EJ[A4#LJ85G"(&(+!5S@?)<;4N"XT\N
MJ\)5*"G4S'B:..P]+%9IBJE/ 0S+ _ZNU9O,,#A:-)5<N^OM4\+5Q-2"E1IX
MZI/%T)5\1ZN1RSMRQ,<Y4W;#Y7*C-T<'1@\1+"5O[2A#ZM7K2DJ>)5"TZD:4
M9-U)4X1@X4X-HHHKX#3^DCZ ****-/Z2  =ISD@<@\]B,?0=<CT8 ]0*_13]
MFK]I5;Y=.^''Q'U%5OE6.Q\)^*;V;+:@2XBMM"UZXD(VWF"D.E:I.?\ 2OEL
MKV3SA!//^==>D_"WX7>)?BQXEA\/^'H4CAC"7&LZS<H[:;H6G%MK7MXR@>9,
MQRFGZ?&XN=0N0L<6R))YHOW?Z.OB+XE^'?B7D6)\,<)C,\S7.\;A,GQG!].%
M:M@>+L)6K*4LKQE"F^2E4IP=?%87-K4ZF23I5,QEB*>#I8^EB?B>.^'N'\]X
M?QE/B"I2PF$P=&IB:&92<:<\JKQIRY<52J2^).T85,)JL93;P\:4JU2A4I_N
M 05)5@0RD@@C!!!P00>1R**Q?#FBKX<T#1M 74M3U@:-IMIIO]JZU/\ :M6U
M#[+$L7VJ_N, 23R;>BKMCC5(@TFSS'*_Z*L%5Q-?!8.OC,)]0QE;"86MB\#]
M8I8OZEBJN'HU<3@_K="%.AB_JM>I5PWUFC3A2K.A*K3BJ=2FW_!-6-.%6K&E
M5]M2C4JQI5N25+VU.%6K"G6]E/\ >4E6IPA6C2J?O*<:JA42G&2/41]U/]T?
MS-/,<BJ&:.15.,,T;JIST^8J!SVYY[4P' C(ZA01W[D]#P>0.M?*M]X1\5>'
MO'_CO5/!=AK6FSZIXJ^$FE:%KMW!K?BG2M,T+Q9'>#XGZUI^B:IJ<NC7B6<I
MAN[^22,6^D2QQ"+['!)(C<7&'%F*X3HY/B*'#V*X@H8_,ZF!QT,!5:Q^!HQR
M^OC:>(PV#>#K0Q\JM2@L)"C4Q>64E6Q%&53&TX*NZ/QV2911S>>,I5,QP^75
M,/A/K-&6*A_L]5K$0HSA5K*M3G1C3A*6(G*E1Q=1TJ554\/.:C&?U51_@1^'
M<?3U%?(<_CG]HBVN_'L%WX;U62WTRX-GHSZ7X+%Q-;Q+XKL].T[7=,N1IL^G
M:_:7_AIKG5=7AMF\07UG,PFL-+@B@DLAUWPCU7XKZKXM-]\0V\0:=!K/PU\/
M7\&B7/A=+'PO:>*;35-:LM85IQ \FBZPT$.E:C<:7-(CZG%JK[(WM=,M4A^*
MRCQJR?.\\RO(<)PAX@X?%9CCZ^"K8G-.%\3E67Y;"AF.=94\5B\9BTL.Z=7'
MY+.AA\-2KQQE=XO#^SBG"K&K[>-X%QN!P&+S#$9QP].EA</"O[+#9C]:K8AU
M,+A,7"G0ITX1<K4\5:I.7+"G*C5=Y07,OI'9(!NV2!2-VXJP4C/W@Q&",D<@
MD9(YR:38_)V-@*&/RGA2,ACQPI'(/0CO7QEI.E>(].\&VGB9= ^*L_QB\":U
MHGB[QY8W[^*9=,\>2V?B&]M?$&D>&EFO9O#NLPWWAS5+M]#M]!MXHXM/BT^W
MN(DGAC5-#P]X?\1Z=XA\/77Q)T[XF:O:ZIX?TSQ'H;^%YO$USIWAGXB^)/%^
MK:[XGM?$,6B7\!L#IVGWN@Z79R:VLF@VF@Z5J%DJ*7GBFY,)XSXW$RRFD_#_
M #3#_P!J4<HQE3'5\7BUD^3X+.,17P-..>9G#A&4L%F^!S7!8W(\SRBEEN*G
MALWAA$L='*\=2S>.U;@>A1ABI?VY@Y_5I8VE]5CAJ4<9C<1@*=/$3^H4)9MR
M8C"5\'5I9AA,;4K488C"N:ITGC*4\&OKS! !(.#G!(X..#@]\=_K00P7>00I
M)7>1@$@<C)Z\8!QGTKYP\2GXHVWQ)\4IX2DU+3-,\0ZSX!T]]=E\/KXBTK3=
M)L_ 7C6]UBZTZSOG33K?/B"UT/3KJY39']KO+.&Y65WB4^2I??'BRNM>^(T6
MBZRGBCQ%8?"_1=0A/@V2Z_X1W2[CP??:IKKZ#HPM-2GFBM?&$-GIVKPG3-1D
MM'OY9)HTNHXIX:SWQLIY+C<7A)^'G'N,AE>:YM@\SQ669'6QV'AEV4SS*,\Q
MP$Z-/VF85J\<+EE2C@G1P5'V.;^W_M.K2RS,+&7\!O,*-*O'B'A^@\7A,)6P
M]'$8I4L1+$8F-"4<+B(/3#J$)8K]]SU9-X6SP]-UZ:C]T9[9]\>_K^0_2CTX
M(R PR.H.<$>H.#R*^0]>\1?'35O#WC*W9O%?A?7[+P]X7O\ 0].\)?#[[39:
MA;K;^$;WQ%J5CXHO'EO!XA>]G\2V+>#DC^W"RLS:"W5V>:2#5/$7QCT2Y\2+
MX6T/7(X-0\4>,=8TN_B^',FIS^,/$7E>$(] T[Q#:W%U"GA#1O$%J^L7>HZ]
M#%9VME<6;V43VO\ 9[QW&6)\=,LPU1-\$>(,\']7J5O;QX<Q+Q4YPKXO"+#_
M -G0P\J^$JQQ6$C2JK-*V'L\=E4*49ULSP:F4N <7.G9YUD$,0YQA[)XYJC!
M.G0KRG/%2C&G4@\/7=2$L+3Q%_88IU%2IX:O4I_8=%?*VK^+?CW9R>))X+=S
M#<-\1(-$M4^'D^K)H+>'_%'A^Q\*W*SZ3#<:AK;>)=$U'6'M9;C3[R&2*SCU
M1+&[6UNDF^AO!][J^I>$_#6H:_9WVGZY>Z)87.L66IP6MKJ-MJ,L(:YBO;6Q
M_P!#MK@/EI(;;$:%MHB@(:%/M.%?$++^+,SQN4X;(N+<HQ."P4\?*IQ#D-?*
ML-6PZS.IEE+ZO7J2G"K6K\L,;"ASQJT\)4?MH+$4JU.EX>;<.8G*<%0QM7'9
M5BZ6(KK#1CE^-6)JPJ_5%BIJM#DIN"IW>'F[-/$0DH.=%TJU34\1_P#'MH'_
M %Y7_P#Z=KRN6KJ?$?\ Q[:!_P!>5_\ ^G:\KEJ^JJ_Q)>K_ #9[N _W'!_]
M@U'_ -)9\N_M@?#GQI\4O@XOA7X;:9X^N_B&OC;POK/@S7OAU\?;G]FW6/A]
MKVF_VA]F^(6K?$>UT7Q9+>>%?#:3RGQ!X#7P-X\C\<V]Y%HTWA*_C+7=A\<?
MMD_"GQLG_!/+P3HO[6NO?%[]I7XF?![X@?"SXI>,/C)^R+X*^&7A3XF:)X^\
M">+[[4/ /Q>\'_!?XB2#X>_$RT\%ZKJ/A_P[XF\!ZC8Q_P#"=1WUWXN;PWI3
MVTUIIGZTTY'>-@\;,CCHZ,589!!PRD$<$C@]"1WK,ZS\!+[X+_M67/C3_@D'
M\6/B_P#L83^*OVC/V?OB9XR\2_M,_%+X$^%?@-X<T7P7\*->T#XU^!/!O@J>
MPL?B/X<T>P\6V]UXX\,_$WXL>#OA?87?P_BUR]\1:CX=U?6[ZSL-.KTO]L;X
M??M8?%KQ]\*OVAOV??V=/C/\.?VL?!7A[QQ\$/A\_BJ;]D;XF?LSP_#RX_:,
M\-ZUJNM_M$#Q]J&H>-=!\.>-?"O@RR^(WA?5/@]IH\>Z3I6J67AU[BV\21ZA
M:5^UP &< #.,X[XZ9^G;TH'' X'MQVQ_+CZ4 ?SP_L[_ +&W[3G@_P#X*31?
M&G5/A#XWTGP1X?\ VV/^"@_Q3U7QAXUA^!EO\%HO@7^TMX<MM/\ #'B[X-ZY
MX3U<?M&^(_C/XRUS1]"M+_PU\3K?4_ 'A?PBVL75MI>AZM=-=M_0]1@>@HH
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M +^1_P#Q5?O3_P (?X/_ .A1\*_^$YHO_P @T?\ "'^#_P#H4?"O_A.:+_\
M(-/_ (IH\0VM_P 1<R:W;_5#.+;M[?VUW;?JV^KN?\3$9?>_^J>8W_[&F#_^
M9K?AOKNVW^"WF1?\]8O^_L?_ ,51YL7_ #UB_P"_L?\ \57[T_\ "'^#_P#H
M4?"O_A.:+_\ (-:=MX,\&G2-9<^#O"1=)]%57/AC0BZK)+?[U5S8%@K^6NY0
M0&VKD<<K_BFAG_7Q<R2/F^#\Z:_\ESB3_"W</^)B<O\ ^B4S#_PZ8/\ ^93\
M _-B_P">L7_?U/\ XJE,L9Q^]BX&/]:G_P 57[T?\(=X/'_,H^%?_";T4?RL
M0*/^$/\ !_\ T*/A7_PG-%_^0:/^*:/$'_1V\E_\0_./_GTOZ[:H/^)B,OO?
M_5/,+]_[3P7_ ,RZ'X+>9%_SUB_[^Q__ !5'F1?\]8O^_L?_ ,57[T_\(?X/
M_P"A1\*_^$YHO_R#1_PA_@__ *%'PK_X3FB__(-'_%-#B#_H[>2_^(?G'_SZ
M#_B8G+_^B4S#_P .F#_^9C\%O,B_YZQ?]_8__BJ/,B_YZQ?]_8__ (JOWI_X
M0_P?_P!"CX5_\)S1?_D&C_A#_!__ $*/A7_PG-%_^0:/^*:/$#W\7,E=MK\(
M9P[>E\ZT]-O(2^D1EZO_ ,8GF.N__"I@_P!<,_PL?@MYD7_/6+_O['_\51YD
M7_/6+_O['_\ %5^]/_"'^#_^A1\*_P#A.:+_ /(-'_"'^#_^A1\*_P#A.:+_
M /(-'_%-'B#3_C;>2Z;?\8?G&G73_A:TUUTZZ[C_ .)B<O\ ^B3S'7_J:8/\
MOJUON2\[GX+>9%_SUB_[^1__ !5'FQ?\]8O^_J?_ !5?O3_PA_@__H4?"O\
MX3FB_P#R#2-X.\'E6!\(^%2"#G/AO1?3_KQ//I[]:?\ Q32XAT7_ !%W)K+1
M7X0SJR3>NBSK;JTD[]F["_XF(R[_ *)/,?\ PZX2WW?5[6OK:UKZVOJ?@OYL
M7_/6+_O['_\ %4>9%_SUB_[^Q_\ Q5?O_KW@OP9'K%\B>#O"2*KP;53PQH2*
M/]$MB<*E@JC)R3@#))/4DUD_\(?X/_Z%'PK_ .$YHO\ \@TO^*:&?]/%S)&N
MZX/SE)_*6<Q?X>@_^)B<O_Z)3,/_  Z8/]<*?@MYD7_/6+_O['_\51YD7_/6
M+_O['_\ %5^]/_"'^#_^A1\*_P#A.:+_ /(-'_"'^#_^A1\*_P#A.:+_ /(-
M'_%-#B#_ *.WDO\ XA^<?_/H/^)B<O\ ^B4S#_PZ8/\ ^9C\%O,B_P">L7_?
MV/\ ^*H\R+_GK%_W]C_^*K]Z?^$/\'_]"CX5_P#"<T7_ .0:/^$/\'_]"CX5
M_P#"<T7_ .0:/^*:'$'_ $=O)?\ Q#\X_P#GT'_$Q.7_ /1*9A_X=,'_ /,Q
M^"WF1?\ /6+_ +^Q_P#Q5'F1?\]8O^_L?_Q5?O3_ ,(?X/\ ^A1\*_\ A.:+
M_P#(-'_"'^#_ /H4?"O_ (3FB_\ R#1_Q30X@_Z.WDO_ (A^<?\ SZ#_ (F)
MR_\ Z)3,/_#I@_\ YF/P6\R+_GK%_P!_8_\ XJCS(O\ GK%_W]C_ /BJ_>G_
M (0_P?\ ]"CX5_\ "<T7_P"0:/\ A#_!_P#T*/A7_P )S1?_ )!H_P"*:'$'
M_1V\E_\ $/SC_P"?0?\ $Q.7_P#1*9A_X=,'_P#,Q^"WFQ?\]8O^_L?_ ,51
MYD7_ #UB_P"_L?\ \57[^V7@SP:^G:\7\'>$F,=KIFPMX9T1BN[5(PVUOL.Y
M"RDHQ1E)0LA.":R_^$/\'CIX1\*#Z>&]%'_MC1_Q30S_ $MXN9(^Z7!V=)KR
M?-G"3_[=;7GL'_$Q.7_]$IF'_ATP?_S*?@MYD7_/6+_O['_\51YD7_/6+_O[
M'_\ %5^]/_"'^#_^A1\*_P#A.:+_ /(-'_"'^#_^A1\*_P#A.:+_ /(-'_%-
M#B#_ *.WDO\ XA^<?_/H/^)B<O\ ^B4S#_PZ8/\ ^9C\%O,B_P">L7_?V/\
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MGOD]??GO0,YST(R 1UP><9X.,\XZ9K1_M)O^?#2/_!>O_P =H_M)O^?#2/\
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M]_%BX^!EY:>!/$/AWQE^T#^RW\.I/AU\&_C3XC\9:GX?/C&.[TZ)-+\8>+O
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MC1KO#SE*=%U*:B_9RDY+=V4TD4445ZQRA1110 4444 %%%% &MI__(-\0_\
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MTKQMX+TC7-9M=2NH_L=W=?KU+^PQ^RG>?&[XK?M"ZO\ !KPCX@^)?QG\%?\
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MO\27J_S9]]@/]QP?_8-1_P#26+129'J/S%&1ZC\Q69UBT4F1ZC\Q1D>H_,4
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MHV_[?O?^>.F?^";1_P#Y H_M^]_YXZ9_X)M'_P#D"L2B@#;_ +?O?^>.F?\
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M_,</E&!QV88^6 X.RFJZ%#!2Q+=U-1C5GB,/@L=B\/&AB)IT,%B?:U*-:G[
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M$/\ UZZ7_P"G2.LF@#;_ +?O?^>.F?\ @FT?_P"0*/[?O?\ GCIG_@FT?_Y
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M +5G_)R/QH_['B^_]);*OV(K\=_VK/\ DY'XS_\ 8[WOYFTLL_K7^>'[2/\
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M?$/_ "&]0_W[?_TCMJQJ "BBB@ HHHH **** "BBB@#6T_\ Y!OB'_KUTO\
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M_P#_ $[7E<M74^(_^/;0/^O*_P#_ $[7E<M7%5_B2]7^;/NL!_N.#_[!J/\
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MX?\ #W[1.HF6S\2:OXKT"PO/&&D7-Q=6?BK0KK5[#06\->+TUZ'3]526_?\
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M6#1"=%TUP]I?,-TNJX3_ (F5PI5-FIHV"P9CO+G<3@A<"N:_M&S_ .@%I?\
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M_EK0!DT5K?VC9_\ 0"TO_O[K'_RUH_M&S_Z 6E_]_=8_^6M &316M_:-G_T
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MHHH *1NA^A_E2TC=#]#_ "H VO$/_(;U#_?M_P#TCMJQJV?$/_(;U#_?M_\
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MK;;\6.$[MMO_ (Q?B9:MMO;,.[/JE](;+%'E7"^8JRLG_:>"?S_W4_&/X7^
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0 !1110 4444 %%%% '__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>5
<FILENAME>ex99-1_003.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 ex99-1_003.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1" !, 6T# 2(  A$! Q$!_\0
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M/&6FZW=Z'K/@VX\,^!K=[&WT_3F,>I)<W)U:>.XCMHOR_P#^",]UK6B?&?\
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M7_ >IP:5%+8377AFSUC4;+6;RWT(>,[U;?2?#%_J2I::O?7D$>G->N1&=?\
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MUK,,SSO+<MPN)R[-\!4J1GCYX_*\7&O"&9SQ4\&L+54JN&DJF,@UA56G*?\
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MEXLC\,*UWJ/A+1#-%>PZ;.'LT^<?^"8O_"TOVD?VL_V1_P!AKXU:?KNH1_\
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M$"@+C K&O_A_X"U6[GU#5/!'A'4K^Z<R7-[?^&M&O+NXD( ,D]S<64DTKD
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:BBB@ HHHH **** "BBB@ HHHH **** /_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>6
<FILENAME>ex99-1_004.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 ex99-1_004.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1"  ^ '\# 2(  A$! Q$!_\0
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'ICK[4 ?_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>7
<FILENAME>ex99-1_005.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 ex99-1_005.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1"  A '<# 2(  A$! Q$!_\0
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MT:W\;>"8;>2WTF[^'W@6&\M_'OBEKKPM<Z#KOAC1=6\07_8^$?VW/"_@_P"
M6ES6?BWPS\??CCK>E:'-X5^%_P "O!TT?@?P+K?Q&O;'0OA+\)M6OM,/]C^
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4H?Y"BB@!Z_ZQ/^!?^@T444 ?_]D!

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
